Internal Medicine, Hematology & Oncology · Las Vegas, NV
NPI
1447270087
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
3150 N Tenaya Way, Ste 200
Las Vegas, NV, 89128
Phone (702) 822-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$561K
140,816 services
Medicare patients, 2024
707
Average age 75
Drug cost, 2024
$10.9M
2,986 prescriptions
Company payments, 2025
$7,731
From 55 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ann M Wierman was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 40,290 times for 39 patients. In total Ann M Wierman billed 140,816 services in 85 codes, and Medicare paid $561K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-10-30.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 40,290 | 39 | $0.28 | $11K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 39,752 | 26 | $0.88 | $35K |
| J9267 Injection, paclitaxel, 1 mg | Office | 9,922 | 12 | $0.08 | $810 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 7,808 | 41 | $0.07 | $577 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 5,723 | 41 | $0.09 | $520 |
| 99233 Hospital E&M - Subsequent | Facility | 1,196 | 199 | $85.72 | $103K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 1,083 | 25 | $5.50 | $5,959 |
| 99214 Office E&M - Established | Office | 1,063 | 409 | $86.34 | $92K |
| J7030 Infusion, normal saline solution , 1000 cc | Office | 783 | 74 | $2.04 | $1,596 |
| J3475 Injection, magnesium sulfate, per 500 mg | Office | 772 | 12 | $0.44 | $342 |
| 96415 Chemotherapy Administration | Office | 570 | 37 | $20.01 | $11K |
| 96361 Intravenous Infusion, Hydration | Office | 487 | 44 | $8.74 | $4,257 |
| 96360 Intravenous Infusion, Hydration | Office | 473 | 62 | $22.67 | $11K |
| 96372 Injection Administration | Office | 455 | 85 | $10.05 | $4,573 |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 424 | 117 | $1.02 | $434 |
By year: 2022 $791K for 123,255 services; 2023 $872K for 165,871 services; 2024 $561K for 140,816 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ann M Wierman prescribed most often to Medicare patients was Eliquis (Apixaban), with 174 prescriptions and refills. In total Ann M Wierman wrote 2,986 Medicare prescriptions that cost $10.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 174 | 314 | 47 | $174K |
| Omeprazole Generic | 134 | 224 | 55 | $911 |
| Ondansetron Hcl Generic | 85 | 87 | 46 | $330 |
| Prednisone Generic | 85 | 86 | 38 | $190 |
| Promacta Eltrombopag Olamine | 78 | 80 | 13 | $647K |
| Warfarin Sodium Generic | 76 | 176 | 15 | $428 |
| Xarelto Rivaroxaban | 76 | 179 | 26 | $93K |
| Levothyroxine Sodium Generic | 72 | 170 | 23 | $445 |
| Keytruda Pembrolizumab | 72 | 72 | 16 | $862K |
| Acyclovir Generic | 67 | 153 | 21 | $687 |
| Prochlorperazine Maleate Generic | 57 | 57 | 34 | $1,081 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 54 | 110 | 19 | $371 |
| Revlimid Lenalidomide | 49 | 49 | Under 11 | $798K |
| Imbruvica Ibrutinib | 48 | 48 | Under 11 | $725K |
| Retacrit Epoetin Alfa-Epbx | 48 | 48 | 13 | $46K |
Brand drugs: - claims; generic drugs: 1,680 claims; opioid claims: 93.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ann M Wierman $7,731 ($7,731 in general payments such as food, travel and fees) from 55 companies. The largest payer was Pfizer Inc. with $595.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 25 | $595 |
| AstraZeneca Pharmaceuticals LP AZN | 18 | $466 |
| Incyte Corporation INCY | 11 | $463 |
| Sobi, Inc SOBI.ST | 15 | $460 |
| GlaxoSmithKline, LLC. GSK | 12 | $446 |
| Daiichi Sankyo Inc. 4568.T | 12 | $402 |
| Novartis Pharmaceuticals Corporation NVS | 19 | $378 |
| Abbvie Inc. ABBV | 10 | $332 |
| Astellas Pharma US Inc 4503.T | 8 | $310 |
| Seagen Inc. PFE | 3 | $275 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.